Suppr超能文献

醛固酮浓度和盐皮质激素受体基因型与心力衰竭患者螺内酯钾反应的关系。

Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure.

机构信息

Department of Pharmacy Practice, University of Illinois at Chicago, 60612-7230, USA.

出版信息

Pharmacotherapy. 2010 Jan;30(1):1-9. doi: 10.1592/phco.30.1.1.

Abstract

STUDY OBJECTIVE

To identify patient-specific factors associated with spironolactone-induced potassium level elevation in patients with heart failure.

DESIGN

Prospective cohort study.

SETTING

Two adult heart failure clinics.

PATIENTS

Sixty-two adult (mean +/- SD age 54 +/- 16 yrs) aldosterone antagonist-naïve patients with heart failure.

INTERVENTION

Patients received spironolactone 12.5 mg/day, titrated to 25 mg/day if tolerated.

MEASUREMENTS AND MAIN RESULTS

Blood samples were obtained at baseline, 1 week after spironolactone initiation, and 1 week after spironolactone dose titration for assessment of baseline aldosterone level, serum chemistry, and angiotensinogen (AGT) c.-6G>A and p.M268T and mineralocorticoid receptor (NR3C2) c.215C>G and p.I180V genotypes. Patient characteristics, laboratory values, and genotypes were compared between those whose potassium levels increased by more than 0.5 mEq/L (15 patients) and those with lower potassium level elevations (47 patients) after spironolactone initiation and dose titration. Patients with a greater potassium level elevation had a higher mean +/- SD aldosterone concentration (178 +/- 92 vs 102 +/- 57 pg/ml, p=0.007) and NR3C2 215G allele frequency (50% vs 22%, p<0.01). Aldosterone concentrations positively correlated with diuretic dose (r=0.313, p=0.014) and negatively correlated with serum potassium level (r= -0.319, p=0.012). On regression analysis, factors predictive of potassium level increases greater than 0.5 mEq/L with spironolactone were aldosterone level greater than 150 pg/ml (odds ratio [OR] 30, 95% confidence interval [CI] 3.2-287] and NR3C2 215G carrier status (OR 17, 95% CI 1.6-167).

CONCLUSION

Our data suggest that potassium should be monitored with particular caution when spironolactone is started in patients with heart failure who have evidence of elevated aldosterone levels, such as high diuretic requirements, or the NR3C2 215G allele.

摘要

研究目的

确定与心力衰竭患者螺内酯引起血钾升高相关的患者特异性因素。

设计

前瞻性队列研究。

地点

两个成人心力衰竭诊所。

患者

62 名(平均年龄 54 +/- 16 岁)醛固酮拮抗剂初治的心力衰竭成年患者。

干预措施

患者接受螺内酯 12.5 毫克/天,耐受后滴定至 25 毫克/天。

测量和主要结果

在开始螺内酯治疗后 1 周和开始螺内酯剂量滴定后 1 周,采集血样以评估基线醛固酮水平、血清化学、血管紧张素原(AGT)c.-6G>A 和 p.M268T 以及盐皮质激素受体(NR3C2)c.215C>G 和 p.I180V 基因型。在开始螺内酯治疗和剂量滴定后血钾升高超过 0.5 mEq/L(15 例)和血钾升高较低(47 例)的患者之间比较患者特征、实验室值和基因型。血钾升高较多的患者平均 +/- SD 醛固酮浓度较高(178 +/- 92 与 102 +/- 57 pg/ml,p=0.007),NR3C2 215G 等位基因频率较高(50%与 22%,p<0.01)。醛固酮浓度与利尿剂剂量呈正相关(r=0.313,p=0.014),与血清钾水平呈负相关(r=-0.319,p=0.012)。在回归分析中,螺内酯治疗后血钾升高大于 0.5 mEq/L 的预测因素是醛固酮水平大于 150 pg/ml(比值比[OR]30,95%置信区间[CI]3.2-287]和 NR3C2 215G 携带者状态(OR 17,95% CI 1.6-167)。

结论

我们的数据表明,在心力衰竭患者开始螺内酯治疗时,如果有证据表明醛固酮水平升高,如利尿剂需求高或 NR3C2 215G 等位基因,则应特别谨慎监测血钾。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验